Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?

Toshio Kato, Masahiro Morise, Masahiko Ando, Eiji Kojima, Tomohiko Ogasawara, Ryujiro Suzuki, Joe Shindoh, Masami Matsumoto, Yasuteru Sugino, Masahiro Ogawa, Yasuhiro Nozaki, Tetsunari Hase, Masashi Kondo, Hiroshi Saito, Yoshinori Hasegawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Predicting the feasibility of platinum-based chemotherapy remains an important issue in elderly (over 70 years) patients with non-small cell lung cancer (NSCLC). The aim of this study was to identify the risk factors for the early serious adverse events (SAEs) (during cycles 1–2) in elderly receiving platinum-based chemotherapy, and to explore the clinical characteristics of patients who require early treatment termination without progressive disease (PD). Methods: One hundred and ninety-eight consecutive elderly NSCLC patients receiving platinum-based chemotherapy were retrospectively reviewed. Results: The median age was 73 years (range 70–83). 161 (81 %) were males, and 190 (95 %) were PS 0–1. Fifty-one (29 %) and 39 (19 %) patients developed early non-hematological SAEs and hematological SAEs, respectively. Multivariate analysis identified low serum albumin (<3.0 g/dl) as an independent risk factor for non-hematological SAEs, while low creatinine clearance (<45 ml/min) for hematological SAEs. In all, 24 (12 %) patients needed early treatment termination without PD. The major reason for this event was the development of non-hematological SAEs (4.5 %), followed by grade 2 non-hematological adverse events (AEs) (3 %). In multivariate analysis, age over 75 years and low serum albumin were associated with this event. The median overall survival (OS) in patients with this event was only 6.0 months, while the development of early SAE was not associated with poor OS. Conclusion: Baseline serum albumin might be useful for predicting the feasibility of platinum-based chemotherapy, and the risk estimation of early treatment termination without PD might be beneficial for the treatment selection in elderly NSCLC patients.

Original languageEnglish
Pages (from-to)1629-1640
Number of pages12
JournalJournal of Cancer Research and Clinical Oncology
Volume142
Issue number7
DOIs
Publication statusPublished - 01-07-2016

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
Serum Albumin
Therapeutics
Multivariate Analysis
Survival
Creatinine

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kato, Toshio ; Morise, Masahiro ; Ando, Masahiko ; Kojima, Eiji ; Ogasawara, Tomohiko ; Suzuki, Ryujiro ; Shindoh, Joe ; Matsumoto, Masami ; Sugino, Yasuteru ; Ogawa, Masahiro ; Nozaki, Yasuhiro ; Hase, Tetsunari ; Kondo, Masashi ; Saito, Hiroshi ; Hasegawa, Yoshinori. / Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?. In: Journal of Cancer Research and Clinical Oncology. 2016 ; Vol. 142, No. 7. pp. 1629-1640.
@article{f3f6ed1ee3f543f69d1aa9159152d9bd,
title = "Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?",
abstract = "Purpose: Predicting the feasibility of platinum-based chemotherapy remains an important issue in elderly (over 70 years) patients with non-small cell lung cancer (NSCLC). The aim of this study was to identify the risk factors for the early serious adverse events (SAEs) (during cycles 1–2) in elderly receiving platinum-based chemotherapy, and to explore the clinical characteristics of patients who require early treatment termination without progressive disease (PD). Methods: One hundred and ninety-eight consecutive elderly NSCLC patients receiving platinum-based chemotherapy were retrospectively reviewed. Results: The median age was 73 years (range 70–83). 161 (81 {\%}) were males, and 190 (95 {\%}) were PS 0–1. Fifty-one (29 {\%}) and 39 (19 {\%}) patients developed early non-hematological SAEs and hematological SAEs, respectively. Multivariate analysis identified low serum albumin (<3.0 g/dl) as an independent risk factor for non-hematological SAEs, while low creatinine clearance (<45 ml/min) for hematological SAEs. In all, 24 (12 {\%}) patients needed early treatment termination without PD. The major reason for this event was the development of non-hematological SAEs (4.5 {\%}), followed by grade 2 non-hematological adverse events (AEs) (3 {\%}). In multivariate analysis, age over 75 years and low serum albumin were associated with this event. The median overall survival (OS) in patients with this event was only 6.0 months, while the development of early SAE was not associated with poor OS. Conclusion: Baseline serum albumin might be useful for predicting the feasibility of platinum-based chemotherapy, and the risk estimation of early treatment termination without PD might be beneficial for the treatment selection in elderly NSCLC patients.",
author = "Toshio Kato and Masahiro Morise and Masahiko Ando and Eiji Kojima and Tomohiko Ogasawara and Ryujiro Suzuki and Joe Shindoh and Masami Matsumoto and Yasuteru Sugino and Masahiro Ogawa and Yasuhiro Nozaki and Tetsunari Hase and Masashi Kondo and Hiroshi Saito and Yoshinori Hasegawa",
year = "2016",
month = "7",
day = "1",
doi = "10.1007/s00432-016-2170-z",
language = "English",
volume = "142",
pages = "1629--1640",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "7",

}

Kato, T, Morise, M, Ando, M, Kojima, E, Ogasawara, T, Suzuki, R, Shindoh, J, Matsumoto, M, Sugino, Y, Ogawa, M, Nozaki, Y, Hase, T, Kondo, M, Saito, H & Hasegawa, Y 2016, 'Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?', Journal of Cancer Research and Clinical Oncology, vol. 142, no. 7, pp. 1629-1640. https://doi.org/10.1007/s00432-016-2170-z

Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy? / Kato, Toshio; Morise, Masahiro; Ando, Masahiko; Kojima, Eiji; Ogasawara, Tomohiko; Suzuki, Ryujiro; Shindoh, Joe; Matsumoto, Masami; Sugino, Yasuteru; Ogawa, Masahiro; Nozaki, Yasuhiro; Hase, Tetsunari; Kondo, Masashi; Saito, Hiroshi; Hasegawa, Yoshinori.

In: Journal of Cancer Research and Clinical Oncology, Vol. 142, No. 7, 01.07.2016, p. 1629-1640.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?

AU - Kato, Toshio

AU - Morise, Masahiro

AU - Ando, Masahiko

AU - Kojima, Eiji

AU - Ogasawara, Tomohiko

AU - Suzuki, Ryujiro

AU - Shindoh, Joe

AU - Matsumoto, Masami

AU - Sugino, Yasuteru

AU - Ogawa, Masahiro

AU - Nozaki, Yasuhiro

AU - Hase, Tetsunari

AU - Kondo, Masashi

AU - Saito, Hiroshi

AU - Hasegawa, Yoshinori

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Purpose: Predicting the feasibility of platinum-based chemotherapy remains an important issue in elderly (over 70 years) patients with non-small cell lung cancer (NSCLC). The aim of this study was to identify the risk factors for the early serious adverse events (SAEs) (during cycles 1–2) in elderly receiving platinum-based chemotherapy, and to explore the clinical characteristics of patients who require early treatment termination without progressive disease (PD). Methods: One hundred and ninety-eight consecutive elderly NSCLC patients receiving platinum-based chemotherapy were retrospectively reviewed. Results: The median age was 73 years (range 70–83). 161 (81 %) were males, and 190 (95 %) were PS 0–1. Fifty-one (29 %) and 39 (19 %) patients developed early non-hematological SAEs and hematological SAEs, respectively. Multivariate analysis identified low serum albumin (<3.0 g/dl) as an independent risk factor for non-hematological SAEs, while low creatinine clearance (<45 ml/min) for hematological SAEs. In all, 24 (12 %) patients needed early treatment termination without PD. The major reason for this event was the development of non-hematological SAEs (4.5 %), followed by grade 2 non-hematological adverse events (AEs) (3 %). In multivariate analysis, age over 75 years and low serum albumin were associated with this event. The median overall survival (OS) in patients with this event was only 6.0 months, while the development of early SAE was not associated with poor OS. Conclusion: Baseline serum albumin might be useful for predicting the feasibility of platinum-based chemotherapy, and the risk estimation of early treatment termination without PD might be beneficial for the treatment selection in elderly NSCLC patients.

AB - Purpose: Predicting the feasibility of platinum-based chemotherapy remains an important issue in elderly (over 70 years) patients with non-small cell lung cancer (NSCLC). The aim of this study was to identify the risk factors for the early serious adverse events (SAEs) (during cycles 1–2) in elderly receiving platinum-based chemotherapy, and to explore the clinical characteristics of patients who require early treatment termination without progressive disease (PD). Methods: One hundred and ninety-eight consecutive elderly NSCLC patients receiving platinum-based chemotherapy were retrospectively reviewed. Results: The median age was 73 years (range 70–83). 161 (81 %) were males, and 190 (95 %) were PS 0–1. Fifty-one (29 %) and 39 (19 %) patients developed early non-hematological SAEs and hematological SAEs, respectively. Multivariate analysis identified low serum albumin (<3.0 g/dl) as an independent risk factor for non-hematological SAEs, while low creatinine clearance (<45 ml/min) for hematological SAEs. In all, 24 (12 %) patients needed early treatment termination without PD. The major reason for this event was the development of non-hematological SAEs (4.5 %), followed by grade 2 non-hematological adverse events (AEs) (3 %). In multivariate analysis, age over 75 years and low serum albumin were associated with this event. The median overall survival (OS) in patients with this event was only 6.0 months, while the development of early SAE was not associated with poor OS. Conclusion: Baseline serum albumin might be useful for predicting the feasibility of platinum-based chemotherapy, and the risk estimation of early treatment termination without PD might be beneficial for the treatment selection in elderly NSCLC patients.

UR - http://www.scopus.com/inward/record.url?scp=84966709803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966709803&partnerID=8YFLogxK

U2 - 10.1007/s00432-016-2170-z

DO - 10.1007/s00432-016-2170-z

M3 - Article

VL - 142

SP - 1629

EP - 1640

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 7

ER -